Skip to content

Citius Pharmaceuticals, Inc.: 10-Q filed 2015-05-13

What Citius Pharmaceuticals, Inc. reported in its quarterly report filed 2015-05-13 (fiscal Q2 2015): 21 published measures, 59 facts as tagged in accession 0001477932-15-003063.

This filing

Form
10-Q (quarterly report)
Filed
2015-05-13
Fiscal period
fiscal Q2 2015
Accession
0001477932-15-003063 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-03-31765,756USD
At 2014-09-301,557,461USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-03-31-918,025USD
At 2014-09-30-741,935USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-03-31760,355USD
At 2014-09-301,552,060USD
At 2014-03-3121,928USD
At 2013-09-301,272USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-01-01 to 2015-03-31-345,268USD90
2014-10-01 to 2015-03-31-1,168,976USD182
2014-01-01 to 2014-03-31-90,279USD90
2013-10-01 to 2014-03-31-624,693USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2014-10-01 to 2015-03-31-1,051,705USD182
2014-01-01 to 2014-09-30-183,164USD273
2013-10-01 to 2014-03-31-554,344USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2014-10-01 to 2015-03-31260,000USD182
2013-10-01 to 2014-03-31575,000USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-03-31-7,307,257USD
At 2014-09-30-6,138,281USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-01-01 to 2015-03-31108,765USD90
2014-10-01 to 2015-03-31217,529USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-03-31-608,914USD90
2014-10-01 to 2015-03-31-1,487,819USD182
2014-01-01 to 2014-03-31-49,829USD90
2013-10-01 to 2014-03-31-549,022USD182

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-10-01 to 2015-03-317,500USD182
2014-01-01 to 2014-03-3140,450USD90
2013-10-01 to 2014-03-3175,671USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-03-311,683,781USD
At 2014-09-302,299,396USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-03-31343,442USD
At 2014-09-30106,169USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-01-01 to 2015-03-31608,914USD90
2014-10-01 to 2015-03-311,487,819USD182
2014-01-01 to 2014-03-3149,829USD90
2013-10-01 to 2014-03-31549,022USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-01-01 to 2015-03-31282,238USD90
2014-10-01 to 2015-03-31759,361USD182
2013-10-01 to 2014-03-31437,397USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-03-3131,580,840shares
At 2014-09-3030,025,286shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-03-316,357,651USD
At 2014-09-305,366,321USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2015-03-318,166USD
At 2014-09-3060,317USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2015-01-01 to 2015-03-31-345,268USD90
2014-10-01 to 2015-03-31-1,168,976USD182
2014-01-01 to 2014-03-31-90,279USD90
2013-10-01 to 2014-03-31-624,693USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-01-01 to 2015-03-31217,911USD90
2014-10-01 to 2015-03-31510,929USD182
2014-01-01 to 2014-03-3149,829USD90
2013-10-01 to 2014-03-31111,625USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2015-01-01 to 2015-03-31263,646USD90
2014-10-01 to 2015-03-31318,843USD182
2014-01-01 to 2014-03-31-40,450USD90
2013-10-01 to 2014-03-31-75,671USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2014-10-01 to 2015-03-31237,273USD182
2013-10-01 to 2014-03-31-9,056USD182

Inspect the source

Entity
Citius Pharmaceuticals, Inc. / CIK 0001506251
Captured
2026-09-20T09:12:24.553Z
SEC response SHA-256
dab437b1abcb106ce657672edecf4aab637b5713b2c1870820e246433043b176

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001506251.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))